Yahoo Finance

Global Supraventricular Tachycardia Market to Hit $1 Billion by 2030, Driven by Innovations in Electrophysiology

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Supraventricular Tachycardia - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for ...
Frontiers

Neonatal supraventricular tachycardia: current diagnostic approaches and emerging technologies

Neonatal supraventricular tachycardia (SVT) represents the most common pathological tachyarrhythmia in the neonatal period, with an incidence of 1:250–1000 live births. This review synthesizes current ...
Business Wire

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
Morningstar

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the ...
Healio

FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
The American Journal of Managed Care

FDA Approves Intranasal Etripamil for Type of Arrhythmia

Intranasal etripamil is the first self-administered, on-demand therapy for PSVT, allowing treatment outside healthcare settings. The RAPID trial showed 64% of etripamil-treated patients returned to ...
MedPage Today

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
Seeking Alpha

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
The Globe and Mail

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with ...

CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially ...
Scientific Research Publishing

The Treatment of Paroxysmal Supraventricular Tachycardia and Research Progress ()

Paroxysmal supraventricular tachycardia (PSVT) is a common rapid arrhythmia observed in clinical settings, characterized by abrupt and sustained episodes lasting minutes to hours. It presents ...
USA Today

Bachelorette party accessory Crossword Clue

In case you've faced some hurdles solving the clue, Bachelorette party accessory, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, ...